Stem cell released molecules and exosomes in tissue engineering

Stem cell released molecules (SRM) production employs a proprietary manufacturing process that allows the collection of a wide variety of soluble and properly folded proteins and signaling molecules with complete post-translational modifications and exosome packaging from multiple stem cell types important to immune modulation, and tissue repair and regeneration. The advantages of the process are in the production of biologically active proteins, exosomes, and signaling molecules, developing a “systems therapeutic” yielding a combination of many molecules, that act at multiple targets, resulting in a synergistic therapeutic with emergent therapeutic value. Furthermore, the production of the SRM (stem cell released molecules) does not require downstream solubilization, refolding, or other processes. Additionally, the process offers reduced purification requirements and lower production costs than other pharmacological and biological processes. The production of a “systems therapeutic” with a multitude of molecules represents a multi-targeted, systems biology approach to designing and manufacturing therapeutics, including therapeutics designed to work alone, or augment scaffolding-based and/or cell-based regenerative medicine.